Healthcare [ 13/13 ] | Biotechnology [ 127/164 ]
NYSE MKT | Common Stock
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics.
The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine.
The company is headquartered in Toronto, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 26, 24 | 0.00 Increased by +100.00% | -0.03 Increased by +100.00% |
| Feb 14, 24 | -0.09 Decreased by -50.00% | -0.04 Decreased by -125.00% |
| Nov 13, 23 | -0.05 Increased by +16.67% | -0.05 |
| Aug 14, 23 | -0.07 Increased by 0.00% | -0.06 Decreased by -16.67% |
| Jun 27, 23 | -0.07 Increased by +30.00% | -0.06 Decreased by -16.67% |
| Feb 14, 23 | -0.06 Increased by +40.00% | -0.07 Increased by +14.29% |
| Nov 14, 22 | -0.06 Increased by +45.45% | -0.07 Increased by +14.29% |
| Aug 8, 22 | -0.07 Increased by +22.22% | -0.09 Increased by +22.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 0.00 Decreased by N/A% | -30.33 M Decreased by -182.35% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -11.89 M Decreased by -19.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -12.38 M Increased by +5.21% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -13.72 M Increased by +24.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -10.74 M Increased by +37.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -9.97 M Increased by +43.36% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -13.05 M Increased by +11.29% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Increased by +100.00% | -18.10 M Decreased by -31.35% | Decreased by N/A% Decreased by N/A% |